Teva Pharmaceutical Reports Q1 Earnings Beat and Announces Amylyx Acquisition

Teva Pharmaceutical (TEVA) reported first-quarter revenue of $4.0 billion, a year-over-year increase of 2% and above analyst estimates. The company also announced plans to acquire Amylyx Pharmaceuticals for up to $900 million in cash plus milestones.

By Abdul Rahman Sat, May 16, 2026 at 9:03 PM GMT+3 2 min read · Yahoo Finance · May 16, 2026, 18:03 UTC

Teva Pharmaceutical Reports Q1 Earnings Beat and Announces Amylyx Acquisition

Tickers: $TEVA

Topics: acquisitions earnings_beat pharmaceuticals

Read the full article at Yahoo Finance

More World news

Rival Technologies Index Reveals Gen Z Financial Constraints Amidst Optimistic Outlook PR Newswire · November 12, 2026, 13:42 UTC
Canadian Cybersecurity Job Postings Rise While Entry-Level Opportunities Decline PR Newswire · November 12, 2026, 13:42 UTC
Klarna Appoints Robinhood's Chris Koegel as Chief Financial Officer Seeking Alpha · November 12, 2026, 13:35 UTC
Kyverna Therapeutics Reports Q3 GAAP EPS of -$0.68, Slightly Beating Estimates Seeking Alpha · November 12, 2026, 13:37 UTC
TelyRx Holdings Appoints Co-Founder Benjamin Atkins as Interim CEO Seeking Alpha · November 12, 2026, 13:38 UTC
Nvidia shares fall following analyst downgrades and reports of potential CEO leadership changes Seeking Alpha · November 12, 2026, 13:38 UTC
Technosylva Launches Technosylva Planning Application for Multi-Hazard Utility Risk Management PR Newswire · November 12, 2026, 13:38 UTC
PVH Corp. Announces Global Workforce Reduction of Approximately 4% Seeking Alpha · November 12, 2026, 13:34 UTC
Analysis Reveals 75% of Americans Reside in Car-Dependent Areas PR Newswire · November 12, 2026, 13:38 UTC
ASML Positioned for Potential Stock Split Amid Surging AI Demand and Record Results Motley Fool · November 12, 2026, 13:31 UTC